Evolution of high-resolution CT-scan in ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Title :
Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors
Author(s) :
Forestier, Alexandra [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Le Gouellec, Noémie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Béhal, Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Kramer, Gerdien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sobanski, Vincent [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Dubois, Sandrine Morell [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Lambert, Marc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Hatron, Pierre-Yves [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Hachulla, Eric [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Duhamel, Alain [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Matran, Régis [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Launay, David [Auteur correspondant]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Rémy-Jardin, Martine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Le Gouellec, Noémie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Béhal, Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Kramer, Gerdien [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sobanski, Vincent [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Dubois, Sandrine Morell [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Lambert, Marc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Hatron, Pierre-Yves [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Hachulla, Eric [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Duhamel, Alain [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Santé Publique : épidémiologie et qualité des soins [EA 2694]
Matran, Régis [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Launay, David [Auteur correspondant]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Claude Huriez [Lille]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Rémy-Jardin, Martine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Journal title :
Seminars in Arthritis and Rheumatism
Pages :
1406 - 1413
Publisher :
WB Saunders
Publication date :
2020-12-31
ISSN :
0049-0172
English keyword(s) :
DLCO
HRCT scans
Interstitial lung disease
Pulmonary function test
Systemic sclerosis
HRCT scans
Interstitial lung disease
Pulmonary function test
Systemic sclerosis
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Objective: The aims of our study were to describe the evolution of interstitial lung disease (ILD) extent on HRCT scan in systemic sclerosis (SSc), to identify baseline prognostic factors associated with ILD evolution and ...
Show more >Objective: The aims of our study were to describe the evolution of interstitial lung disease (ILD) extent on HRCT scan in systemic sclerosis (SSc), to identify baseline prognostic factors associated with ILD evolution and to assess whether the evolution of pulmonary function tests (PFTs) correlated with this evolution.Methods: 58 SSc with ILD (SSc-ILD) patients were included. All HRCT scans and PFTs available were collected. We modelized PFTs and HRCT scans evolution using linear mixed model with random effect.Results: Patients underwent a median number of 3 HRCT scans (total n = 203) and 5 PFTs (total n = 329), during a mean follow-up of 5.3 ± 4.9 years. Mean SSc duration was 2.5 ± 3.1 years at the diagnosis of ILD. Mean baseline ILD extent was 32.3 ± 28.7%. We found a significant mean progression of ILD extent on serial HRCT scans of 0.92 ± 0.36% per year (p = 0.018). Male sex, diffuse cutaneous SSc (dcSSc), presence of anti-topoisomerase 1 antibodies, a higher DLCO, limited ILD and a low coarseness score at baseline in bivariate analysis, and presence of antitopoisomerase 1 antibodies and a coarseness score of 0 in multivariate analysis, were associated with faster progression of ILD extent over time There was a significant correlation between the progression of ILD extent and the decline of DLCO but only a trend for FVC. ILD extent at baseline and during follow-up was associated with survival.Conclusion: Male sex, dcSSc, anti-topoisomerase 1 antibodies and a less severe ILD at baseline were associated with a faster progression of ILD over time. Evolution of DLCO significantly correlated with change in ILD extent on HRCT scan. Our study helps defining the profile of patients at risk of experiencing a progression of ILD on HRCT scans.Show less >
Show more >Objective: The aims of our study were to describe the evolution of interstitial lung disease (ILD) extent on HRCT scan in systemic sclerosis (SSc), to identify baseline prognostic factors associated with ILD evolution and to assess whether the evolution of pulmonary function tests (PFTs) correlated with this evolution.Methods: 58 SSc with ILD (SSc-ILD) patients were included. All HRCT scans and PFTs available were collected. We modelized PFTs and HRCT scans evolution using linear mixed model with random effect.Results: Patients underwent a median number of 3 HRCT scans (total n = 203) and 5 PFTs (total n = 329), during a mean follow-up of 5.3 ± 4.9 years. Mean SSc duration was 2.5 ± 3.1 years at the diagnosis of ILD. Mean baseline ILD extent was 32.3 ± 28.7%. We found a significant mean progression of ILD extent on serial HRCT scans of 0.92 ± 0.36% per year (p = 0.018). Male sex, diffuse cutaneous SSc (dcSSc), presence of anti-topoisomerase 1 antibodies, a higher DLCO, limited ILD and a low coarseness score at baseline in bivariate analysis, and presence of antitopoisomerase 1 antibodies and a coarseness score of 0 in multivariate analysis, were associated with faster progression of ILD extent over time There was a significant correlation between the progression of ILD extent and the decline of DLCO but only a trend for FVC. ILD extent at baseline and during follow-up was associated with survival.Conclusion: Male sex, dcSSc, anti-topoisomerase 1 antibodies and a less severe ILD at baseline were associated with a faster progression of ILD over time. Evolution of DLCO significantly correlated with change in ILD extent on HRCT scan. Our study helps defining the profile of patients at risk of experiencing a progression of ILD on HRCT scans.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Collections :
Source :
Files
- document
- Open access
- Access the document
- S0049017220300688.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- S0049017220300688.pdf
- Open access
- Access the document